walgreens boots alliance inc. - WBA

WBA

Close Chg Chg %
8.29 -0.05 -0.60%

Closed Market

8.24

-0.05 (0.60%)

Volume: 25.81M

Last Updated:

Nov 20, 2024, 4:00 PM EDT

Company Overview: walgreens boots alliance inc. - WBA

WBA Key Data

Open

$8.21

Day Range

8.11 - 8.33

52 Week Range

8.11 - 27.05

Market Cap

$7.17B

Shares Outstanding

864.62M

Public Float

710.05M

Beta

0.67

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$10.01

Yield

1,483.72%

Dividend

$0.25

EX-DIVIDEND DATE

Nov 18, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

20.23M

 

WBA Performance

1 Week
 
-2.83%
 
1 Month
 
-23.63%
 
3 Months
 
-20.00%
 
1 Year
 
-60.48%
 
5 Years
 
-86.40%
 

WBA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 21
Full Ratings ➔

About walgreens boots alliance inc. - WBA

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

WBA At a Glance

Walgreens Boots Alliance, Inc.
108 Wilmot Road
Deerfield, Illinois 60015
Phone 1-847-315-3700 Revenue 147.66B
Industry Drugstore Chains Net Income -8,636,000,000.00
Sector Retail Trade 2024 Sales Growth 6.167%
Fiscal Year-end 08 / 2025 Employees 312,000
View SEC Filings

WBA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.054
Price to Book Ratio 0.765
Price to Cash Flow Ratio 7.843
Enterprise Value to EBITDA 9.541
Enterprise Value to Sales 0.274
Total Debt to Enterprise Value 0.837

WBA Efficiency

Revenue/Employee 473,262.821
Income Per Employee -27,679.487
Receivables Turnover 25.236
Total Asset Turnover 1.662

WBA Liquidity

Current Ratio 0.68
Quick Ratio 0.372
Cash Ratio 0.115

WBA Profitability

Gross Margin 16.298
Operating Margin 1.206
Pretax Margin -9.63
Net Margin -5.849
Return on Assets -9.722
Return on Equity -56.695
Return on Total Capital -19.50
Return on Invested Capital -18.869

WBA Capital Structure

Total Debt to Total Equity 324.011
Total Debt to Total Capital 76.416
Total Debt to Total Assets 41.762
Long-Term Debt to Equity 286.089
Long-Term Debt to Total Capital 67.472
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Walgreens Boots Alliance Inc. - WBA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
132.51B 132.70B 139.08B 147.66B
Sales Growth
-5.04% +0.15% +4.81% +6.17%
Cost of Goods Sold (COGS) incl D&A
106.36B 106.43B 114.27B 123.59B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.92B 1.99B 2.26B 2.46B
Depreciation
1.40B 1.35B 1.44B 1.50B
Amortization of Intangibles
523.00M 639.00M 815.00M 963.00M
COGS Growth
-6.24% +0.06% +7.36% +8.16%
Gross Income
26.14B 26.27B 24.82B 24.07B
Gross Income Growth
+0.21% +0.50% -5.56% -3.02%
Gross Profit Margin
+19.73% +19.80% +17.84% +16.30%
2021 2022 2023 2024 5-year trend
SG&A Expense
22.13B 23.50B 21.83B 22.28B
Research & Development
- - - -
-
Other SG&A
22.13B 23.50B 21.83B 22.28B
SGA Growth
-0.97% +6.23% -7.13% +2.09%
Other Operating Expense
- - - -
-
Unusual Expense
959.00M (1.10B) 10.37B 17.71B
EBIT after Unusual Expense
3.06B 3.87B (7.39B) (15.93B)
Non Operating Income/Expense
(573.00M) 507.00M 2.55B 2.20B
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
(1.14B) 418.00M 252.00M 213.00M
Interest Expense
491.00M 396.00M 580.00M 482.00M
Interest Expense Growth
-23.16% -19.35% +46.46% -16.90%
Gross Interest Expense
491.00M 396.00M 580.00M 482.00M
Interest Capitalized
- - - -
-
Pretax Income
2.00B 3.98B (5.42B) (14.22B)
Pretax Income Growth
+168.51% +99.75% -235.98% -162.39%
Pretax Margin
+1.51% +3.00% -3.90% -9.63%
Income Tax
667.00M (30.00M) (1.86B) 1.25B
Income Tax - Current - Domestic
194.00M 76.00M 229.00M 143.00M
Income Tax - Current - Foreign
234.00M 260.00M 283.00M 185.00M
Income Tax - Deferred - Domestic
(56.00M) (98.00M) (2.25B) 1.17B
Income Tax - Deferred - Foreign
295.00M (268.00M) (120.00M) (251.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
(1.14B) 418.00M 252.00M 213.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.96B 4.07B (3.53B) (15.45B)
Minority Interest Expense
(39.00M) (271.00M) (448.00M) (6.81B)
Net Income
1.99B 4.34B (3.08B) (8.64B)
Net Income Growth
+337.28% +117.45% -171.03% -180.39%
Net Margin Growth
+1.50% +3.27% -2.21% -5.85%
Extraordinaries & Discontinued Operations
- - - 226.00M
-
Discontinued Operations
- - - 226.00M
-
Net Income After Extraordinaries
2.22B 4.34B (3.08B) (8.64B)
Preferred Dividends
- - - -
-
Net Income Available to Common
2.22B 4.34B (3.08B) (8.64B)
EPS (Basic)
2.5671 5.0174 -3.5681 -10.0058
EPS (Basic) Growth
+395.10% +95.45% -171.11% -180.42%
Basic Shares Outstanding
864.80M 864.40M 863.20M 863.10M
EPS (Diluted)
2.5623 5.0087 -3.5681 -10.0058
EPS (Diluted) Growth
+394.65% +95.48% -171.24% -180.42%
Diluted Shares Outstanding
866.40M 865.90M 863.20M 863.10M
EBITDA
5.94B 4.76B 5.24B 4.24B
EBITDA Growth
+4.71% -19.86% +10.14% -19.15%
EBITDA Margin
+4.48% +3.59% +3.77% +2.87%

Snapshot

Average Recommendation HOLD Average Target Price 10.207
Number of Ratings 21 Current Quarters Estimate 0.386
FY Report Date 11 / 2024 Current Year's Estimate 1.537
Last Quarter’s Earnings 0.39 Median PE on CY Estimate N/A
Year Ago Earnings 2.88 Next Fiscal Year Estimate 1.46
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 14 17 14
Mean Estimate 0.39 0.52 1.54 1.46
High Estimates 0.48 0.65 1.75 1.66
Low Estimate 0.31 0.42 1.42 1.14
Coefficient of Variance 11.39 11.26 5.53 10.66

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 2
OVERWEIGHT 1 1 2
HOLD 13 12 12
UNDERWEIGHT 1 1 1
SELL 3 3 3
MEAN Hold Hold Hold

Insider Actions for Walgreens Boots Alliance Inc. - WBA

Date Name Shares Transaction Value
Jun 5, 2024 Elizabeth L. Burger EVP, Global Chief HR Officer 160,462 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Lanesha T. Minnix EVP and Global CLO 186,136 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 5, 2024 Mary Langowksi EVP, President U.S. Healthcare 256,739 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2024 Valerie B. Jarrett Director 32,414 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2024 John Anthony Lederer Director 67,724 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 30, 2024 Robert Huffines Director 1,853 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 26, 2024 Tracey D. Brown EVP, Pres., Walgreens Retail 179,869 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 26, 2024 Tracey D. Brown EVP, Pres., Walgreens Retail 176,380 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $18.22 per share 3,213,643.60
Apr 16, 2024 Inderpal S. Bhandari Director 3,000 Open market or private purchase of non-derivative security Non-derivative transaction at $18.05 per share 54,150.00
Mar 7, 2024 Todd Heckman SVP, Global Controller and CAO 41,164 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Manmohan Mahajan EVP and Global CFO 160,969 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2024 Beth Amber L Fabbri Chief Corp. Affairs Officer 52,822 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Walgreens Boots Alliance Inc. in the News